Safety and Immunogenicity of Revaccination with Influenza Vaccine in Healthy Adult Subjects aged 18 to 64 Years who were Previously Vaccinated with Fluzone ID or Fluzone IM

StatusFinished
Effective start/end date11/09/0931/08/10

Funding

  • Sanofi Pasteur, Inc.: $127,350.00

Keywords

  • Biotechnology & Drug Development